Affimed And BioNTech Immunotherapies Among Ones To Watch At AACR
Range Of New Modalities Put To Test
Affimed looks to build on the splash at last year’s American Association for Cancer Research meeting next month, while BioNTech aims to prove its immunotherapy capabilities with a CAR-T candidate.
You may also be interested in...
Under pressure to show Moderna can grow the company’s mRNA vaccines portfolio beyond COVID-19, CEO Stéphane Bancel has talked down his rivals in the field.
Early clinical results for AFM13 combined with NK cells showed high response rates without serious toxicities, and the data could have readthrough to the company’s EGFR-targeted therapy.
Several big pharma companies may be interested in buying Mirati, but could baulk at paying up to $12bn for its as-yet-unproven oncology portfolio.